Depemokimab data reveals 72% reduction in hospitalizations; projected sales hit £4 billion. GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

A new solar farm will provide electricity to a major manufacturer in County Durham. The new facility at Stainton, near Barnard Castle, will power the nearby Glaxo Smith Kline factory for 40 years.

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.

GSK has agreed to buy US biopharmaceutical business IDRx in a deal worth up to $1.15billion (£1billion). Under the agreement, GSK will pay $1billion upfront to acquire the Massachusetts-based ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal cancer asset. “We really became impressed with what IDRx had achieved ...

January 13, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...

GSK fired the opening gun for the 2025 JP Morgan Healthcare Conference on Monday with a front-loaded acquisition agreement, moving to buy precision therapy specialist IDRx and its rare cancer drug ...

Credit: Bloomberg via Getty Images. GSK has announced a definitive agreement to acquire IDRx, a US-based biotechnology company specialising in treatments for gastrointestinal cancers, for up to ...

The company, which was founded by industry veteran GSK Velu, has a track record of acquiring and integrating leading regional diagnostics players and scaling them under the Neuberg platform. Neuberg ...

Founded by Monograph Capital and GSK, the San Francisco–based start-up will have $120 million in starting funds, which it will use to advance its pipeline of T cell engagers and build its discovery ...